Considerations and challenges in defining optimal iron utilization in hemodialysis - sprookjes - yvandenbroek - TriplyDB

Considerations and challenges in defining optimal iron utilization in hemodialysis

Considerations and challenges in defining optimal iron utilization in hemodialysis

http://www.wikidata.org/entity/Q28088564

about

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.Signal-intensity-ratio MRI accurately estimates hepatic iron load in hemodialysis patients.Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.Iron-based phosphate binders--a new element in management of hyperphosphatemia.The Labile Side of Iron Supplementation in CKD Management of the Dialysis Patient with Sickle Cell Disease.Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations.Investigational therapies for renal disease-induced anemia.Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution.Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn).Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis.Serum Ferritin Variations and Mortality in Incident Hemodialysis Patients.Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort.Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD.Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate.Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.Anemia in chronic kidney disease.Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease

P2860

Q26752664-AF6E0392-375C-40B9-B223-3F9D203A1BC2 Q28547636-69E6B3EC-35A1-40FB-A86D-89B6BED1A1A2 Q36123635-24041DDF-1B37-453C-B4EC-936792D88677 Q36194460-86170AFB-FA26-40EC-9E4E-53EED103D279 Q36315311-E857CE9A-F90C-4B9C-BB17-198A07369174 Q36333126-C282DE2F-2DCB-4672-8963-1F4A923F9405 Q36746098-1034D1DD-B696-4680-88D9-1A0EEB937D82 Q37355996-981CE2AC-080A-491D-871B-684201D6DC31 Q37570855-8F5784E1-D53E-4FA8-9A95-759E27A72BF1 Q37664189-70F3E83E-FE68-4973-ABFF-DBF47CFB0C25 Q38295285-0CF716F7-D051-4CF0-8437-F1EB56DB8971 Q38496987-F5402BB5-F8DB-4839-9E97-750ABC8FDFD9 Q38547177-8EBEB902-950E-4E9E-A3E2-1E07575B0B18 Q38761669-2386FD77-9DA9-4B86-8585-DC1E202FC62F Q38819455-93624EC5-F6C4-4ABE-89A2-9509A96109CB Q38884441-70EBB96B-C275-4748-BE92-62882505D189 Q39022863-A4C0BCE6-BA97-4BE6-8B2D-31503CE42E69 Q39216391-C5ACC5BD-6132-4861-B0BB-9EE90B760EDB Q40123974-AE6C2F08-A781-4B61-B21C-497EA9A51E73 Q40340927-38187EEB-E159-43D7-8A25-CC6EB0BAC7CE Q43236775-346BFD54-58AD-447F-ACA2-13583F95DEFF Q45853530-75389B0E-FF21-4767-A384-EBDFD06A0D23 Q47805747-462B471A-F2F8-47D9-A093-2F1FA0B77F8B Q48252464-B5E4DFFC-C5AE-4633-BFC5-420F8E237CA1 Q53354670-ADED264C-720E-4586-9387-BF0F4D8C8BA0 Q53823548-2F9A6948-150B-4282-AF7F-63B0C6CB5E59 Q58700150-25D7BEAA-9765-4946-992E-693FBE755275

P2860

Considerations and challenges in defining optimal iron utilization in hemodialysis

http://www.wikidata.org/entity/Q28088564

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Considerations and challenges in defining optimal iron utilization in hemodialysis

@ast

Considerations and challenges in defining optimal iron utilization in hemodialysis

@en

Considerations and challenges in defining optimal iron utilization in hemodialysis

@nl

type

label

Considerations and challenges in defining optimal iron utilization in hemodialysis

@ast

Considerations and challenges in defining optimal iron utilization in hemodialysis

@en

Considerations and challenges in defining optimal iron utilization in hemodialysis

@nl

prefLabel

Considerations and challenges in defining optimal iron utilization in hemodialysis

@ast

Considerations and challenges in defining optimal iron utilization in hemodialysis

@en

Considerations and challenges in defining optimal iron utilization in hemodialysis

@nl

P1433

Q28088564-5AD1B1D3-4C58-48CF-BDAD-F36B332C771B

P1476

Q28088564-323EE39F-1666-43E7-BE46-DAEB14EA4A3E

P2093

Q28088564-12860848-53A5-41C4-A3FB-0C41711A8C04

Q28088564-5C58ACAC-476D-457A-8D2A-419279902DC5

Q28088564-600E77FE-8E01-456E-90D0-05D4B8C92556

Q28088564-6EC2E095-9562-4A77-9FB2-99D1D9872AD9

Q28088564-8D2055A2-6A79-4082-A74A-B6761B980AF7

Q28088564-8EB96E50-802B-41C0-9B67-C0B237DA2723

Q28088564-CFF12B90-495D-4C18-A741-185563E994A0

P2860

Q28088564-039EDE92-DB66-4DA7-BAC1-977439921120

Q28088564-04A25B7C-470F-4F54-8D5D-01D241CB8B25

Q28088564-0893C14D-4D93-42C9-B719-5A8FF14CD45F

Q28088564-08D8F2CD-F431-4B96-9FE1-8E8D3318F352

Q28088564-0DF6ECC5-5EF1-4093-BC64-135817600DC7

Q28088564-11AACBA3-CDA3-4D82-B0FA-EAE7F4C0FCDC

Q28088564-16F9BC49-756E-4367-B6ED-03053C62E66E

Q28088564-19355E49-D247-4FD9-8DB5-0D500CB37229

Q28088564-1B9EADB4-DC89-4AE6-85DC-DE24333400F3

Q28088564-1DD5EB6A-A2BF-4AD3-B00A-178F94682CFF

P304

Q28088564-3731258C-E259-4DA4-92AA-7088424B6648

P31

Q28088564-12C5D111-2DFB-42F5-98D6-44391FB9B523

P3181

Q28088564-5E72BAAE-893B-4DBD-994F-AC5DBAA2CDEA

P356

Q28088564-5B2477E4-1D57-45D8-A04F-97D66C196E30

P407

Q28088564-697E2266-FD1A-47BA-B007-83532900BC6A

P433

Q28088564-0ADA6B87-12A8-464A-96EF-58D9D0AE8E41

P478

Q28088564-2086EFDF-608E-4D13-AE5D-6C73E98704CB

P577

Q28088564-7E938597-EBC1-45B7-A995-2C1DC50627D7

P5875

Q28088564-FED84D2B-47E4-476C-8958-62A2DDBA6BC8

P698

Q28088564-7F07CEB5-A268-47E0-A015-5E5299968E55

P932

Q28088564-2D2EC298-6486-41C7-8A89-55CF93E2E125

P3181

P356

P1433

Journal of the American Society of Nephrology

P1476

Considerations and challenges in defining optimal iron utilization in hemodialysis

@en

P2093

A. B. Pai

http://www.w3.org/2001/XMLSchema#string

A. M. Hung

http://www.w3.org/2001/XMLSchema#string

C. P. Kovesdy

http://www.w3.org/2001/XMLSchema#string

C. T. Chan

http://www.w3.org/2001/XMLSchema#string

D. M. Charytan

http://www.w3.org/2001/XMLSchema#string

D. W. Coyne

http://www.w3.org/2001/XMLSchema#string

S. Fishbane

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

Identification of erythroferrone as an erythroid regulator of iron metabolism

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Acute-phase proteins and other systemic responses to inflammation

A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications

Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival.

Staphylococcus aureus bacteremia and buttonhole cannulation: long-term safety and efficacy of mupirocin prophylaxis

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Nanomedicine(s) under the microscope.

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.

P304

1238-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2251136

http://www.w3.org/2001/XMLSchema#string

P356

10.1681/ASN.2014090922

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270106918

http://www.w3.org/2001/XMLSchema#string

P698

25542967

http://www.w3.org/2001/XMLSchema#string

P932

4446883

http://www.w3.org/2001/XMLSchema#string